{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:23:27Z","timestamp":1791890607833,"version":"4.3.4"},"reference-count":115,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA223301"],"award-info":[{"award-number":["CA223301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL144113"],"award-info":[{"award-number":["HL144113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI130131"],"award-info":[{"award-number":["AI130131"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL143402"],"award-info":[{"award-number":["HL143402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Abl1 kinase has important biological roles. The Bcr-Abl1 fusion protein creates undesired kinase activity and is pathogenic in 95% of chronic myeloid leukemia (CML) and 30% of acute lymphoblastic leukemia (ALL) patients. Targeted therapies to these diseases are tyrosine kinase inhibitors. The extent of a tyrosine kinase inhibitor\u2019s targets determines the degree of biologic effects of the agent that may influence the well-being of the patient. This fact is especially true with tyrosine kinase inhibitor effects on the cardiovascular system. Thirty-one percent of ponatinib-treated patients, the tyrosine kinase inhibitor with the broadest inhibitory spectrum, have thrombosis associated with its use. Recent experimental investigations have indicated the mechanisms of ponatinib-associated thrombosis. Further, an antidote to ponatinib is in development by re-purposing an FDA-approved medication.<\/jats:p>","DOI":"10.3390\/ijms21186556","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:03:48Z","timestamp":1599555828000},"page":"6556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis"],"prefix":"10.3390","volume":"21","author":[{"given":"Peng","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Schmaier","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Knight, T.G., Grunwald, M.R., and Copelan, E.A. (2019). Concise Guide to Hematology, Chapter 25, Chronic Myeloid Leukemia, Springer Nature. [2nd ed.].","DOI":"10.1007\/978-3-319-97873-4_25"},{"key":"ref_2","unstructured":"Institute, N.C. (2020, July 01). Cancer Stat Facts: Leukemia\u2014Chronic Myeloid Leukemia (CML), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"ref_3","unstructured":"Association, A.C. (2020, July 01). Cancer Facts and Figures. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer\u2212org\/research\/cancer\u2212facts\u2212and\u2212statistics\/annual\u2212cancer\u2212facts\u2212and\u2212figures\/2019\/cancer\u2212facts\u2212and\u2212figures\u22122019.pdf."},{"key":"ref_4","first-page":"151","article-title":"Blut","volume":"36","author":"Virchow","year":"1845","journal-title":"Frorieps Notizen."},{"key":"ref_5","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from the suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinb. Med. Surg. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/1881165a0","article-title":"A possible specific chromosome abnormality in human chronic myeloid leukaemia","volume":"188","author":"Baikie","year":"1960","journal-title":"Nature"},{"key":"ref_7","first-page":"545","article-title":"Chromosome studies in human leukemia. III. Acute granulocytic leukemia","volume":"29","author":"Hungerford","year":"1962","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood.V68.6.1369.1369","article-title":"bcr rearrangement and translocation of the c\u2212abl oncogene in Philadelphia positive acute lymphoblastic leukemia","volume":"68","author":"Hagemeijer","year":"1986","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: From molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.11248","article-title":"Targeted therapy and the T315I mutation in Philadelphia\u2212positive leukemias","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: A historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia\u2212specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Daley","year":"1986","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/283826a0","article-title":"Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine","volume":"283","author":"Witte","year":"1980","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1073\/pnas.78.3.1552","article-title":"Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine","volume":"78","author":"Sefton","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0092-8674(80)90554-1","article-title":"Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: Studies with cloned viral DNA","volume":"22","author":"Goff","year":"1980","journal-title":"Cell"},{"key":"ref_18","first-page":"2213","article-title":"Lymphosarcoma: Virus\u2212induced thymic\u2212independent disease in mice","volume":"30","author":"Abelson","year":"1970","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1073\/pnas.87.15.5802","article-title":"The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases","volume":"87","author":"Kruh","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: Evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01454-13","article-title":"The capable ABL: What is its biological function?","volume":"34","author":"Wang","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0092-8674(91)90011-M","article-title":"Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c\u2212abl proto\u2212oncogene","volume":"65","author":"Tybulewicz","year":"1991","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1073\/pnas.0913131107","article-title":"c\u2212Abl tyrosine kinase regulates cardiac growth and development","volume":"107","author":"Qiu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0896-6273(00)80646-7","article-title":"Essential roles for the Abl and Arg tyrosine kinases in neurulation","volume":"21","author":"Koleske","year":"1998","journal-title":"Neuron"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12432","DOI":"10.1073\/pnas.1304188110","article-title":"Abl kinases are required for vascular function, Tie2 expression, and angiopoietin\u22121\u2212mediated survival","volume":"110","author":"Chislock","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ra51","DOI":"10.1126\/scisignal.2002632","article-title":"Abl family kinases modulate T cell\u2212mediated inflammation and chemokine\u2212induced migration through the adaptor HEF1 and the GTPase Rap1","volume":"5","author":"Gu","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chislock, E.M., and Pendergast, A.M. (2013). Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0085231"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2007-10-118232","article-title":"The c\u2212Abl tyrosine kinase regulates actin remodeling at the immune synapse","volume":"112","author":"Huang","year":"2008","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1465-9921-14-105","article-title":"Role of Abl in airway hyperresponsiveness and airway remodeling","volume":"14","author":"Cleary","year":"2013","journal-title":"Respir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/embor.2010.195","article-title":"An evolutionarily acquired genotoxic response discriminates MyoD from Myf5, and differentially regulates hypaxial and epaxial myogenesis","volume":"12","author":"Innocenzi","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/bj20021539","article-title":"Cbl\u2212ArgBP2 complex mediates ubiquitination and degradation of c\u2212Abl","volume":"370","author":"Soubeyran","year":"2003","journal-title":"Biochem. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/sj.onc.1208454","article-title":"Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress","volume":"24","author":"Cao","year":"2005","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","article-title":"Bcr\u2212Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis","volume":"117","author":"Sun","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-18-0901","article-title":"Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1097-2765(00)00138-6","article-title":"Cytoskeletal protein PSTPIP1 directs the PEST\u2212type protein tyrosine phosphatase to the c\u2212Abl kinase to mediate Abl dephosphorylation","volume":"6","author":"Cong","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.aap8210","article-title":"LZTR1 is a regulator of RAS ubiquitination and signaling","volume":"362","author":"Bigenzahn","year":"2018","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1242\/jcs.035691","article-title":"SHP\u22122 is a novel target of Abl kinases during cell proliferation","volume":"121","author":"Mitra","year":"2008","journal-title":"J. Cell Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32313","DOI":"10.1074\/jbc.M111.249060","article-title":"Inhibition of protein\u2212tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr\u2212Abl protein","volume":"286","author":"Alvira","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nature14231","article-title":"Signalling thresholds and negative B\u2212cell selection in acute lymphoblastic leukaemia","volume":"521","author":"Chen","year":"2015","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14739","article-title":"Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia","volume":"178","author":"Zhang","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2017.250","article-title":"SHP2 is required for BCR\u2212ABL1\u2212induced hematologic neoplasia","volume":"32","author":"Gu","year":"2018","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"ref_43","first-page":"1","article-title":"Molecular insights into the Philadelphia translocation","volume":"5","author":"Heisterkamp","year":"1991","journal-title":"Hematol. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e963450","DOI":"10.4161\/23723548.2014.963450","article-title":"Re\u2212evaluating the role of BCR\/ABL in chronic myelogenous leukemia","volume":"1","author":"Ross","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"Grosveld","year":"1982","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR\u2212ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular\u2212defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR\u2212ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MOH.0000000000000111","article-title":"Preleukemia: The normal side of cancer","volume":"22","author":"Shlush","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR\u2212ABL1\u2212Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/s41467-020-16927-w","article-title":"Synergism between IL7R and CXCR4 drives BCR\u2212ABL induced transformation in Philadelphia chromosome\u2212positive acute lymphoblastic leukemia","volume":"11","author":"Abdelrasoul","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: A population\u2212based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.28106","article-title":"Trends in all\u2212cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis","volume":"119","author":"Brunner","year":"2013","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-6-70","article-title":"Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century","volume":"6","author":"Pulte","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE\u22125, a population\u2212based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: Findings from a UK population\u2212based patient cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Beinortas, T., Tavoriene, I., Zvirblis, T., Gerbutavicius, R., Jurgutis, M., and Griskevicius, L. (2016). Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: A report from population\u2212based Lithuanian haematological disease registry 2000\u20132013. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2238-9"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Di Felice, E., Roncaglia, F., Venturelli, F., Mangone, L., Luminari, S., Cirilli, C., Carrozzi, G., and Giorgi Rossi, P. (2018). The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: A population\u2212based study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4984-3"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Knight, J.D., Qian, B., Baker, D., and Kothary, R. (2007). Conservation, variability and the modeling of active protein kinases. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000982"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Uitdehaag, J.C., de Roos, J.A., van Doornmalen, A.M., Prinsen, M.B., de Man, J., Tanizawa, Y., Kawase, Y., Yoshino, K., Buijsman, R.C., and Zaman, G.J. (2014). Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092146"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2014-01-453134","article-title":"Src family kinases: At the forefront of platelet activation","volume":"124","author":"Senis","year":"2014","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29183","DOI":"10.1074\/jbc.C000326200","article-title":"Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl\u2212terminal Src kinase, Csk","volume":"275","author":"Takeuchi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood-2017-02-768077","article-title":"Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148","volume":"131","author":"Mori","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1538-7836.2012.04814.x","article-title":"Distinct and overlapping functional roles of Src family kinases in mouse platelets","volume":"10","author":"Severin","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood.V96.13.4246","article-title":"Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway","volume":"96","author":"Quek","year":"2000","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1038\/sj.onc.1208081","article-title":"Structure and regulation of Src family kinases","volume":"23","author":"Boggon","year":"2004","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e957508","DOI":"10.4161\/21688362.2014.957508","article-title":"The angiopoietin\u2212Tie2 signaling axis in the vascular leakage of systemic inflammation","volume":"3","author":"Milam","year":"2015","journal-title":"Tissue Barriers"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI\u2212571 cancer therapy caused by BCR\u2212ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR\u2212ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR\u2212ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate\u2212resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)\u2212LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia\u2212positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan\u2212BCR\u2212ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation\u2212based resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non\u2212ATP\u2212competitive inhibitor of BCR\u2212ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic\u2212phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome\u2212positive chronic myeloid leukemia in chronic phase: ENESTnd 3\u2212year follow\u2212up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long\u2212term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5\u2212year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib\u2212resistant CML and Philadelphia chromosome\u2212positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib\u2212resistant Philadelphia chromosome\u2212positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome\u2212positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open\u2212label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","article-title":"Ponatinib as second\u2212line treatment in chronic phase chronic myeloid leukemia patients in real\u2212life practice","volume":"97","author":"Breccia","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2212positive leukemia: Final 5\u2212year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real\u2212life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","article-title":"Real\u2212life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study","volume":"18","author":"Raanani","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_91","unstructured":"Administration, U.F.a.D. (2020, July 01). Ponatinib (Marketed as Iclusig) Information, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-requires-multiple-new-safety-measures-leukemia-drug-iclusig.informaton."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular Toxic Effects of Targeted Cancer Therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Cirmi, S., El Abd, A., Letinier, L., Navarra, M., and Salvo, F. (2020). Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers, 12.","DOI":"10.3390\/cancers12040826"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1055\/s-0039-1688787","article-title":"Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response","volume":"119","author":"Hamadi","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_97","unstructured":"Center, M.D.A.C. (2020, July 01). Phase II Nilotinib with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00129740."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic\u2212phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR\u2212ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine\u2212based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","article-title":"Absorption, metabolism, and excretion of [(14)C]ponatinib after a single oral dose in humans","volume":"79","author":"Ye","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Schmaier, A. (2019). Concise Guide to Hematology, Chapter 10, Physiology of Hemostasis, Springer Nature. [2nd ed.].","DOI":"10.1007\/978-3-319-97873-4_10"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaau0731","DOI":"10.1126\/sciadv.aau0731","article-title":"Ponatinib (AP24534) inhibits MEKK3\u2212KLF signaling and prevents formation and progression of cerebral cavernous malformations","volume":"4","author":"Choi","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fcvm.2018.00125","article-title":"Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation","volume":"5","author":"Chen","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/ATVBAHA.118.312315","article-title":"Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation","volume":"39","author":"Li","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0703407","article-title":"Apoptosis in the vasculature: Mechanisms and functional importance","volume":"130","author":"Mallat","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14483","DOI":"10.1073\/pnas.94.26.14483","article-title":"Localization of a constitutively active, phagocyte\u2212like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II","volume":"94","author":"Pagano","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/HYPERTENSIONAHA.115.03622","article-title":"Nox and Inflammation in the Vascular Adventitia","volume":"67","author":"Meijles","year":"2016","journal-title":"Hypertension"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: The forgotten, cost\u2212effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMcibr1511276","article-title":"Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR\u2212gamma Agonist","volume":"373","author":"Egan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/18\/6556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:07:49Z","timestamp":1760177269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/18\/6556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":115,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21186556"],"URL":"https:\/\/doi.org\/10.3390\/ijms21186556","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}